BMRN:NASDAQ
Biomarin Pharmaceutical Inc
54,56 USD
arrow_downward
-1,17%(-0,65) 1D
8-окт., 14:06:29 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
54,95 USD
High
54,95 USD
Low
53,90 USD
Mkt. cap
10,56 млд
Avg. vol.
2,03 млн
Volume
800,88 миң
P/E ratio
147,08
52-wk high
70,98 USD
52-wk low
49,26 USD
EPS
0,37 USD
Beta
0,22
Shares outstanding
193,57 млн
No. of employees
3 миң
Open
54,95 USD
High
54,95 USD
Low
53,90 USD
Mkt. cap
10,56 млд
Avg. vol.
2,03 млн
Volume
800,88 миң
P/E ratio
147,08
52-wk high
70,98 USD
52-wk low
49,26 USD
EPS
0,37 USD
Beta
0,22
Shares outstanding
193,57 млн
No. of employees
3 миң
News stories
From web sources and news partners
Simply Wall Street
·
1 саат мурун
Is BioMarin Pharmaceutical (BMRN) Below Fair Value After New Clinical Data And Its AI Deal?
Zacks
·
1 күн мурун
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
AD HOC NEWS
·
1 күн мурун
BioMarin flags USD 283 million charge. BioMarin stock loses 1.83 percent.
TradingView
·
1 күн мурун
BioMarin Q3 financial results to see IPR&D expense impact of $283M
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22 миң
Foundedмар. 1997
HeadquartersСан Рафаел, Калифорния, Америка Кошмо Штаттары
Sector-
Websitebiomarin.com